AstraZeneca to buy Alexion for $39 billion to expand in immunology
Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases.
Saturday, December 12, 2020
AstraZeneca to buy Alexion for $39 billion to expand in immunology
AstraZeneca to buy Alexion for $39 billion to expand in immunology
Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases.
Related Posts:
Why bond investors are willing to bet on money-losing Pemex after oil price crash- Rudderless after a rally, stock markets look for next catalyst
- Dozens of Chinese companies added to U.S. blacklist in latest Beijing rebuke
- Oil falls as China omits 2020 growth target amid pandemic
- GOP weighs jobless aid cuts to urge Americans back to work
0 comments:
Post a Comment